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1178preliminary data produced con-
ﬂicting results about urine output,
and few studies had been done
in patients with chronic heart
failure.
With concerns raised about
the effects of nesiritide on both
mortality and renal function
(1,2), the ASCEND-HF (Acute
Study of Clinical Effectiveness of
Nesiritide and Decompensated
Heart Failure) was created. TheTable 1
Candidate Predictor Variables Considered
in the Models
Continuous variables
Age
Systolic blood pressure (SBP)
Diastolic blood pressure (SBP)
Heart rate
Respiration rate
B-type natriuretic peptide (BNP) or N-terminal (NT) pro-BNP
Serum creatinine
Serum blood urea nitrogen (BUN)
Serum sodium
Serum potassium
Total dose of loop diuretics given in ﬁrst 24 h
Body mass index (BMI)
Categorical variables
Sex
Race
Orthopnea
Dyspnea
Previous weight gain
Paroxysmal nocturnal dyspnea
Pulmonary congestion or edema with rales or crackles
Elevated jugular venous pressure (JVP)
S3
Mitral regurgitation
History of coronary artery disease (CAD)
Peripheral edema
Hospitalized for heart failure within the past year
History of chronic respiratory disease
History of diabetes mellitus
Treatment with nesiritide or placebo
New York Heart Association (NYHA) class
Previous weight gain refers to the investigator’s determination as to whether ﬂuid had been
recently retained by the patient.results of this large study have been previously published; the
ASCEND-HF found nesiritide to have minimal effects on
survival, hospitalizations, and symptoms (3). Yet, whether or
not nesiritide increases diuresis in patients with heart failure
remains unknown. Furthermore, the factors that predict
and affect urine output in this patient population are not well-
studied or understood. Knowing that the effects of nesiritide
on urine output in patients with heart failure is an important
clinical question, the investigators of the ASCEND-HF
collected data about the acute actions of nesiritide on renal
function.We used these data to assess the impact of nesiritide
on urine output and to determine the factors that lead to
diuresis.
Methods
The ASCEND-HF was a randomized, double-blind,
placebo-controlled trial in which nesiritide was adminis-
tered in addition to standard care. The details of the
methodology and enrollment criteria for the ASCEND-HF
have been previously published (3). The study was approved
by each participating center’s ethics committee or institu-
tional review board, and all participants provided written
informed consent.
A total of 7,141 patients were randomized, and 7,007
patients received the study drug. In 5,864 of these patients,
24-h urine output was measured. Subjects with urine output
greater than the 99th percentile (>7,700 ml) were excluded
from these analyses because of suspicion that the data might
be incorrect. To assure accurate assessment of urine volume,
we excluded the countries that reported less than 60% of these
measurements (Australia, Canada, Germany, New Zealand,
and Sweden). A sensitivity analysis, including all patients,
yielded the same independent predictors of urine output.
A total of 5,320 patients received loop diuretics and had
dose data recorded; of these, 80% received intravenous
furosemide. For the purpose of this analysis, other loop
diuretics were converted to “furosemide equivalent doses.” A
dose of 40 mg of intravenous furosemide was considered
equivalent to 20 mg of both intravenous and oral torsemide,
1 mg of both intravenous and oral bumetanide, and 80 mg of
oral furosemide.
Factors that might impact urine output were analyzed by
generalized linear modeling. A total of 4,881 patients hadcomplete data and comprise the sample reported in these
analyses.
Data analysis. All pre-speciﬁed discrete variables are re-
ported as frequencies and counts. Median and the 25th and
75th percentiles are reported for continuous factors.
Normality is tested using the Kolmogorov-Smirnov
statistic. All continuous variables reported in Table 1 were
found to be non-normally distributed. The p values re-
ported in Table 2 are generated from the Wilcoxon rank
sum test and report a non-parametric p value. Generalized
linear modeling was generated to assess the pre-speciﬁed
factors’ relationship to outcomes. Pre-speciﬁed baseline
factors are reported in Table 1. Modeling assumptions were
veriﬁed and residual plots were generated between potential
predictors and outcomes. Transformations were used when
necessary. The log transformation was used for urine
output, blood urea nitrogen (BUN), and diuretic dose. The
stepwise procedure with inclusion level set to <0.05 was
used to attain the signiﬁcant predictors of outcome. We
generated the main effect for each variable on outcome and
interaction between the main effects and treatment. No
adjustments for multiple comparisons were made. All
Table 2
Baseline Characteristics in Patients With Urine Output Above and Below the
Median Value
Output 2,250 ml Output >2,250 ml p Value
Age, yrs 65 (55, 75) 68 (57, 77) <0.001
Male, % 63.1 69.5 <0.001
Race, % <0.001
White 50.8 54.2
Black 11.8 18.5
Asian 33.5 22.3
Other 4.0 5.0
CAD, % 56.5 52.6 0.003
Hypertension, % 69.7 74.4 <0.001
NYHA class before decompensation NS
I 3.7 4.6
II 18.1 18.6
III 49.0 48.3
IV 29.3 28.5
Dyspnea NS
At rest 61.8 63.8
Minimal exertion 38.2 36.2
Orthopnea, % 74.2 78.2 <0.001
Pulmonary edema, % 69.2 80.1 <0.001
Weight gain, % 59.2 71.3 <0.001
Baseline sodium, mmol/l 139 (136, 141) 139 (136, 141) NS
Baseline creatinine, mg/dl 1.2 (1.0, 1.5) 1.2 (1.0, 1.6) NS
Estimated GFR, ml/min/1.73 m2 61 (45, 77) 59 (44, 74) 0.0015
Baseline BUN, mg/dl 24 (17, 37) 26 (18, 39) <0.001
Baseline BUN/creatinine ratio 20 (15, 27) 21 (16, 28) <0.001
Baseline BNP (pg/ml [n ¼ 2,173]) 991 (546, 1,844) 988 (540, 1,819) NS
Baseline NT pro-BNP (pg/ml [n ¼ 3,208]) 4,791 (2,279, 9,179) 4,091 (1,868, 8,877) 0.002
Ejection fraction, % 30 (30, 37) 30 (20, 36) NS
Values are mean  SD or n (%).
GFR ¼ glomerular ﬁltration rate; other abbreviations as in Table 1.
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9.0 software (SAS Institute Inc., Cary, North Carolina).Table 3 Final Model of Predictors of Urine Output
Parameter Estimate
Standard
Error t Value Pr > jtj
Baseline BMI 0.0073 0.0011 6.64 <0.0001
Baseline diastolic BP 0.0035 0.0006 5.74 <0.0001
Male sex 0.1139 0.0174 6.54 <0.0001
Previous weight
gain?
0.0999 0.0182 5.48 <0.0001
Jugular venous
distension
0.0927 0.0169 5.47 <0.0001
Log BUN 0.0885 0.0145 6.10 <0.0001
Log diuretic dose 0.0900 0.0111 8.13 <0.0001
BP ¼ blood pressure; other abbreviations as in Table 1.Results
Of the 5,864 subjects with urine output measurements,
66% were male, 52% were classiﬁed as white, 15% as black,
and 28% as Asian. The median (25th, 75th percentile)
age was 66 (56, 76) years. Body mass index (BMI) was
27.4 (23.7, 32.5) kg/m2, systolic blood pressure was
123 (110, 140) mm Hg, diastolic blood pressure was
75 (67, 84) mm Hg, and heart rate was 82 (72, 95) beats/
min. The ejection fraction was 30% (20%, 36%) in the 4,562
subjects in whom it was assessed.
Recent weight gain was reported in 65% of subjects, 63%
reported dyspnea at rest, 37% reported dyspnea on minimal
exertion, 72% had a history of hypertension, 35% had a
history of myocardial infarction, and 42% had diabetes mel-
litus. Baseline creatinine was 1.2 (1.0, 1.6) mg/dl and BUN
was 25 (18, 38) mg/dl. B-type natriuretic peptide was mea-
sured in 2,181 subjects and was 990 (543, 1,825) pg/ml,
whereas NT pro-BNP was 4,460 (2,051, 9,030) pg/ml in
3,211 subjects.Baseline characteristics of patients divided by urine
output above and below the median value of 2,250 ml are
shown in Table 2. After 24 h, BUN increased 0.0 (3.0,
4.0) mg/dl in the low urine output group and 1.4 (2.0,
5.5) mg/dl in the high urine output (p < 0.0001). Urine
output in the ﬁrst 24 h correlated with the improvement in
dyspnea, with a Spearman’s rank correlation coefﬁcient of
0.123 (p < 0.0001).
Figure 1
Effect of Nesiritide on Log Furosemide Dose in
Selected Subgroups
The ﬁgure demonstrates a comparison of nesiritide and placebo on log
furosemide dose in patients within various subgroups. Groups are divided by
median. There were no differences between nesiritide and placebo. Note that
although the median was equivalent in all subgroups, the 75th and 99th
percentiles were higher in those with an elevated creatinine, an elevated BUN, and
a lower DBP; the differences between patients with a creatinine, BUN, or DBP
below and above the median was signiﬁcant (p < 0.0001). BUN ¼ blood
urea nitrogen (mg/dl); Creat ¼ creatinine (mg/dl); DBP ¼ diastolic blood
pressure (mm Hg); Plac ¼ placebo.
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modeling of factors that predicted urine output (including all
parameters listed in Table 1) are shown in Table 3. The
statistically signiﬁcant predictors are shown. Diuretic dose
was a strong predictor of urine output. A doubling of the log
diuretic dose was independently associated with a 7% increase
in the log urine output. The relatively modest increase in
urine output may have been the result of the higher doses
needed in patients with worse renal function (Fig. 1) for
similar urine output (Table 4). The relationship between
furosemide dose and urine output is demonstrated in
Figure 2. There was a correlation between log urine output
and log dose, with a Spearman’s rank correlation coefﬁcient
of 0.154 (p < 0.0001). Also predictive of increased urine
output were male sex, higher BMI, higher diastolic blood
pressure, the presence of elevated jugular venous pressure,
recent weight gain, and a lower BUN.
The increased log urine output in men (12% more than in
women) was associated with 7% higher log diuretic doses;
however, male sex predicted increased urine output, even
after controlling for BMI and diuretic dose. Similarly, larger
people (determined by BMI) received higher doses of di-
uretics. Patients with higher BUN concentrations received
more diuretics (Fig. 1), but they had less urine output
(Table 4). A doubling in the log of the BUN was associated
with a 6% decrease in log urine output.
Diastolic blood pressure also predicted urine output.
Patients with lower pressures had less urine output, despite
higher diuretic doses. For a 5-U increase in diastolic blood
pressure, there was a 2% increase in log urine output. Patients
with evidence of ﬂuid retention (those with reported weight
gain from baseline and those with elevated jugular venous
pressures) also received higher diuretic doses and had more
diuresis.
Effects of nesiritide. The 24-h urine output was 2,280
(1,550, 3,280) ml for patients who received nesiritide and
2,200 (1,550, 3,200) ml for those who received placebo (p ¼
NS). The dose of loop diuretic was 80 (40, 140) mg in both
patients receiving nesiritide and patients receiving placebo
(p ¼NS). Because it was important to determine if nesiritide
increased urine output in some subgroups, we modeled the
proven predictors with the addition of nesiritide. As shown in
Table 5, nesiritide did not increase the urine output after
adjustment for all independent predictors of urine output.
Unadjusted comparison of urine output with nesiritide
and placebo in various subgroups is shown in Table 4. There
is no difference between the treatments regarding subgroups
of blood pressure, weight gain, jugular venous pressure, sex,
and age. Subjects with a creatinine or BUN above the median
had a small statistically signiﬁcant increase with nesiritide.
In hopes of deﬁning subgroups that may beneﬁt from
nesiritide, we further assessed factors that might interact with
nesiritide by looking at interaction terms between nesiritide
and the independent predictors of urine output in the ﬁnal
model. None of these interaction terms affected the predic-
tion of urine output.
Table 4 Log Urine Output by Characteristics That Predicted Urine Output
Planned Nesiritide Planned Placebo p Value
eGFR (median 59.5 ml/kg/min)
Below median 7.72 (7.31, 8.09) 7.65 (7.31, 8.04) 0.015
Above median 7.74 (7.38, 8.10) 7.74 (7.38, 8.13) 0.560
Creatinine (median 1.21 mg/dl)
Below median 7.72 (7.33, 8.06) 7.70 (7.37, 8.10) 0.657
Above median 7.76 (7.38, 8.12) 7.70 (7.31, 8.07) 0.024
BUN (median 25.06 mg/dl)
Below median 7.74 (7.35, 8.09) 7.74 (7.38, 8.13) 0.418
Above median 7.73 (7.36, 8.10) 7.65 (7.31, 8.04) 0.006
Previous weight gain
Yes 7.80 (7.39, 8.16) 7.77 (7.38, 8.15) 0.305
No 7.63 (7.30, 7.94) 7.60 (7.26, 7.94) 0.479
Jugular venous distension
Yes 7.78 (7.42, 8.12) 7.76 (7.41, 8.13) 0.495
No 7.65 (7.28, 8.04) 7.63 (7.26, 8.01) 0.229
Diastolic BP (median 75 mm Hg)
Below median 7.70 (7.31, 8.06) 7.67 (7.31, 8.04) 0.332
Above median 7.76 (7.38, 8.13) 7.74 (7.38, 8.15) 0.354
Age (median 66 yrs)
Below median 7.78 (7.38, 8.13) 7.74 (7.38, 8.10) 0.068
Above median 7.69 (7.31, 8.04) 7.67 (7.31, 8.06) 0.907
BMI (median 27.4 kg/m2)
Below median 7.66 (7.31, 8.02) 7.60 (7.28, 7.97) 0.026
Above median 7.81 (7.04, 8.16) 7.80 (7.43, 8.19) 0.788
Sex
Male 7.76 (7.38, 8.13) 7.74 (7.38, 8.10) 0.114
Female 7.66 (7.24, 8.01) 7.64 (7.28, 8.01) 0.853
Values are median (25th, 75th percentile).
eGFR ¼ estimated glomerular ﬁltration rate; other abbreviations as in Table 1.
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The ASCEND-HF showed no evidence that nesiritide in-
creases urine output in patients with ADHF. Furthermore,
we could ﬁnd no subgroup in which nesiritide increased
urine output. Although there was a slight increase in
patients with worse renal function, this increase was not
independent of the factors that predicted urine output. The
interaction terms between treatment and BUN, creatinine,
and estimated glomerular ﬁltration rate (eGFR) were not
signiﬁcant. We also found no evidence to support the
hypothesis that the use of nesiritide may decrease the
amount of diuretics needed for diuresis (4,5). Although this
may be surprising to those who believe that nesiritide
increases urine output, this ﬁnding is consistent with
previous data.
Previous studies that have found nesiritide to have an effect
on sodium and urine output have not studied the ADHF
patient population. In a randomized, blinded, crossover study
comparing placebo and nesiritide, there was no effect on urine
output in patients receiving loop diuretics (6). Rather, in-
creased urine output with physiological or usual pharmaco-
logical doses of BNP has only been proven in normal
individuals (7,8). Interestingly, there is also evidence thatwhen nesiritide is given after cardiac surgery it increases urine
output (9). If this is true, then the acute nature of the
depressed urine output in these patients could explain why
they respond differently than patients with chronic heart
failure. Although the ASCEND-HF evaluated patients with
ADHF, most had chronic disease that could have affected the
renal results.
Heart failure patients may respond differently to nesiritide
than healthy individuals. For example, vascular effects of
BNP differ between patients with and without heart failure
(10). Similarly, a differential response to nesiritide on uri-
nary sodium excretion was seen in one study, with heart
failure patients having a urinary sodium excretion of 27
mmol/min as compared with 190 mmol/min in subjects
without heart failure (11). It is also possible that neuro-
hormonal activation limits the efﬁcacy of natriuretic pep-
tides. Multiple neurohormonal systems affect urine output,
and the impact of natriuretic peptides has been shown to
be modiﬁed by the renin-angiotensin-aldosterone (12) and
sympathetic nervous systems (13). There is also a decreased
response in high output failure that is associated with neu-
rohormonal activation (14).
The concentration of nesiritide may also affect the urine
output. In a small study, doses higher than those presently
Figure 2
Relationship Between Furosemide Dose and
Urine Volume
The ﬁgure displays the relationship between furosemide dose (in those who
received intravenous furosemide) and urine volume. There was a correlation
between log urine output and log dose, with a Spearman’s rank correlation
coefﬁcient of 0.154 (p < 0.0001).
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such doses also have greater hemodynamic effect, which has
led to the use of the lower doses than those studied in the
ASCEND-HF.
Predictors of urine output. In patients hospitalized for
ADHF, diuresis is often a chief goal of therapy. Although
the relationship between ﬂuid loss and dyspnea improve-
ment was statistically signiﬁcant, the correlation was not
strong. Furthermore, increased urine output was associated
with increased BUN, indicating evidence of increased
neurohormonal activation. These ﬁndings suggest that the
cause of decompensation is multifactorial and is usually not
simply ﬂuid retention. Nevertheless, understanding the
factors that lead to diuresis is important because many
patients do present with ﬂuid overload.
Two main factors appeared to affect the ability of patients
to diurese: 1) the dose of diuretic administered; and 2) sickerTable 5
Final Model of Predictors of Urine Output
With Treatment Added
Parameter Estimate Standard Error t-value Pr > jtj
Baseline BMI 0.0073 0.0011 6.33 <0.0001
Baseline diastolic BP 0.0035 0.0006 5.74 <0.0001
Male sex 0.1134 0.0174 6.51 <0.0001
Previous weight
gain?
0.0999 0.0182 5.48 <0.0001
Jugular venous
distension?
0.0927 0.0169 5.47 <0.0001
Log BUN 0.0885 0.0145 6.09 <0.0001
Log diuretic dose 0.0902 0.0111 8.14 <0.0001
Treatment 0.0199 0.0163 1.22 0.222
Abbreviations as in Tables 1 and 3.patients are more refractory to diuresis. Not surprisingly,
diuresis increased when larger doses were administered. The
dose of diuretics was not randomized and thus characteris-
tics that were associated with higher diuretic doses were not
randomly distributed and often also predicted urine output.
Many factors can affect the dose given, but the present
study suggests that it is not merely refractoriness of diuretics
that causes larger doses to be given, but rather that it is the
physician’s reluctance to give higher doses that may limit
adequate diuresis.
Larger patients, men, and those who had more ﬂuid
overload (having elevated jugular venous pressure or recent
weight gain) received higher doses of diuretics and urinated
more. From the data collected, it is impossible to know if
these patients needed more diuresis and were therefore more
aggressively diuresed, or if the physician’s subjective factors
had inﬂuenced the dosing. Although these factors are
associated with diuretic dose, they were also independently
associated with urine output. Regardless of these factors, the
ﬁnding that higher doses of diuretics were used and that
there was more urine output in patients with a higher BMI
suggests that larger size (which was also associated with men)
causes physicians to be more comfortable with prescribing
higher doses of diuretics.
There does not appear to be neurohormonal reasons
why women should have less diuresis. Indeed, sex differences
in neurohormonal response to endothelin would be expected
to lead to more urine output in women (16). Similarly,
testosterone activates the renin angiotensin system, so that
one might expect men to have decreased urine output (17).
As a result, the differences between men and women are
more likely to be related to diuretic doses or renal function.
The second main cause of decreased diuresis, suggested by
our study, is expected; sicker patients are more refractory to
diuresis. Renal dysfunction, as assessed by eGFR and BUN
concentrations, was associated with less urine output despite
higher diuretic doses. Yet, interestingly, BUN was more
predictive than eGFR, perhaps because BUN reﬂects both
renal function and avidity for urine retention. An increased
BUN/creatinine ratio reﬂects neurohormonal activation,
with associated elevations in plasma renin activity, arginine
vasopressin, and endothelin concentrations (18,19). In-
creases in BUN probably reﬂect neurohormonal activation
more than any fall in glomerular ﬁltration rate (20), and
BUN plus the BUN/creatinine ratio are more prognostic
than creatinine (18,20–22). Even the association of loop
diuretics and mortality may be related to the elevated BUN
in patients receiving higher doses of loop diuretics, again
suggesting that the elevated BUN reﬂects neurohormonal
activation (23). Although renal dysfunction is undoubtedly
important, the fact that BUN independently predicts urine
output suggests that the physiology leading to an elevated
BUN is also important.
Despite receiving higher doses of diuretics, those patients
with a lower diastolic blood pressure had less urine output.
This may reﬂect the severity of their heart failure, but it
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perfusion pressure affects natriuresis induced by natriuretic
peptides (24). Similarly, after renal transplantation, higher
nocturnal blood pressure was associated with increased
urine output (25).
Conclusions
By examining data from the ASCEND-HF, we found that
urine output was most strongly related to diuretic dose,
suggesting that physicians can often increase diuresis simply
by increasing the diuretics. Nevertheless, neurohormonal
activation (as evidenced by BUN concentration) and lower
blood pressure limit diuresis. Nesiritide did not lead to
increased urine output in patients with ADHF. As a result,
new interventions are needed for patients who are refractory
to conventional diuretics.
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